Clinical Trial

ZR-MTX for PIOL Phase II Trial

Study acronym: ZR-MTX
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective single-arm phase II study, with the purpose of evaluating the efficiency of ZR-MTX regimen (Rituximab, Zanubrutinib and methotrexate) combined with intravitreal methotrexate, then followed by minimal residual disease directed Zanubrutinib maintenance in newly-diagnosed primary intraocular lymphoma. The primary endpoint of this study is progression-free survival (PFS).
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-08
Trial Details
NCT Number NCT06973811
Lead Sponsor Peking Union Medical College Hospital
Conditions Primary Intraocular Lymphoma
Enrollment 47 participants
Start Date 2025-05-21
Primary Completion 2027-10-30 (estimated)
Study Completion 2029-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-07